Bicycle Therapeutics Announces First Patient Dosed in Phase IIa Trial of Bicycle® Toxin Conjugate BT1718 September 2, 2020
Bicycle Therapeutics Announces First Patient Dosed in Oxurion’s Phase II Trial Using a Novel Bicycle®-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema September 1, 2020
Bicycle Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update August 6, 2020
Bicycle Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update May 7, 2020
Bicycle Therapeutics Announces First Patient Dosed in Phase I Dose Escalation of BT5528 in Combination with Nivolumab May 5, 2020
